Cancer Biology

Timing of treatment shapes the path to androgen receptor signaling inhibitor resistance in prostate cancer

1. Eugine Lee
2. Zeda Zhang
3. Chi-Chao Chen
4. Danielle Choi
5. Aura C. Agudelo Rivera
6. Eliot Linton
7. Yu-jui Ho
8. Jillian Love
9. Justin LaClair
10. John Wongvipat
11. Charles L. Sawyers

• Curated by eLife

  eLife assessment

  This important study provides new insight into the dynamics that underlie the development of therapy resistance in prostate cancer by revealing that divergent tumor evolutionary paths occur in response to different treatment timing and that these converge on common resistance mechanisms. The use of barcoded lineage tracing and characterization of isolated tumor clonal populations provides compelling evidence supporting the importance of clonal dynamics in a tumor ecosystem for treatment resistance. Several open questions remain, however, raising the possibility of alternative interpretations of the data set in its current form. Overall, the findings deepen our understanding of prostate cancer evolution and hold promising implications for how drug resistance can be addressed or prevented.

Reviewed by eLife

Elevated FOXG1 supports exit from quiescence in neural stem cells through FoxO6

1. Kirsty M Ferguson
2. Carla Blin
3. Claudia Garcia-Diaz
4. Harry Bulstrode
5. Raul Bardini Bressan
6. Katrina McCarten
7. Steven M. Pollard

Reviewed by Review Commons